# Pediatric Healthcare Market > Middle East and Africa Pediatric Healthcare Market Research Report Information By Type Of Diseases (Short Term Diseases, Chronic Diseases And Others), By Therapeutics (Cardiology, Allergy and Immunology, Gastroenterology, Infectious Disease and Others), By Treatment (Medication, Surgery, and Others) And By Region (Middle East and Africa) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.84% - **2024:** $ 50.01 Billion - **2025:** $ 51.93 Billion - **2035:** $ 75.71 Billion - **Key Players:** Roche(CH), Pfizer (US), Novartis (CH), Sanofi (FR), GlaxoSmithKline (GB), Merck (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Johnson & Johnson (US) **Report ID:** MRFR/Pharma/2061-HCR · **Pages:** 72 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/pediatric-healthcare-market-2778 --- ## Market Summary ## **Middle East and Africa Pediatric Healthcare Market Overview** Middle East and Africa Pediatric Healthcare Market Size was valued at USD 47.91 Billion in 2023. The Pediatric Healthcare market industry is projected to grow from USD 50.01 Billion in 2024 to USD 67.62 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.84% during the forecast period (2024 - 2032). Population grows, increasing costs for healthcare, expanding knowledge and instruction, technological progress, disease incidence, are the key market drivers enhancing the market growth. Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review In January 2024, COPE Health Solutions is on the brink of establishing its inaugural pediatric COPE Health Scholars Program in collaboration with Children's Hospital of Orange County (CHOC), a pediatric healthcare system located in Southern California. The COPE Health Scholars programs are experiential educational and career ladder programs that provide students and community members with educational and training opportunities to advance their careers in healthcare.. The program provides direct patient care and prepares the scholars with a career development pathway by offering clinical and administrative rotations with nurses, doctors, other care team members, and administrators. CHOC will be the first pediatric health site in the country to offer this innovative program when it launches in January 2024. The COPE Health Scholar program is intended for high school graduates, college students, and career changers. It comprises online coursework, a minimum of 280 hours of in-person experience at CHOC, and access to the most suitable training and employment opportunities. Through the Health Scholar program, COPE Health Solutions has a longstanding commitment to providing high-quality experiential education that is directly linked to targeted career training and employment placement, thereby enhancing the quality, diversity, and accessibility of the health care workforce. This program provides a fully immersive experience that includes training and employment opportunities to work across a broad spectrum of healthcare, which is of interest to many of our current Scholars and alumni who are interested in pursuing careers in pediatrics. Apollo, an integrated healthcare provider, has implemented an industry-first pediatric ProHealth Programme in July 2023 to address the growing prevalence of non-communicable diseases (NCDs) among children and adolescents. The Pediatric ProHealth Programme is initiated by Apollo to combat the increasing prevalence of non-communicable diseases in minors. The program conducts routine screenings and customizes tests based on family history and age. Apollo Children's operates 40 hospitals, has more than 900 dedicated beds, and employs 400 specialized pediatricians who offer specialized services in more than 25 specialized care specialties. With the objective of establishing a state-of-the-art, dedicated network to redefine pediatric healthcare. Apollo Children's will provide specialized interventions for a variety of complex medical and surgical paediatric conditions, such as congenital disorders, gastrointestinal and liver disorders, neurodevelopmental disorders, cardiac conditions, renal disease, oncology, and liver transplanting. A dedicated emergency department will be staffed by specialists and equipped with advanced life-saving apparatus as a component of their 24/7 paediatric emergency and intensive care services, ensuring the immediate and efficient management of emergencies. ## **Pediatric Healthcare Market Trends** ### **Increasing changes in lifestyle is driving the market growth** The pediatric healthcare market in the Middle East and Africa (MEA) is a vibrant and quickly expanding industry that caters to the medical requirements of children in the area. It includes a wide range of medical services, such as screening, diagnosis, treatment, and specialised care for newborns, kids, and teenagers. Due to high birth rates and an expanding healthcare system, the MEA region has a sizable and growing population of youngsters. There is a considerable demand for pediatric healthcare services thanks to this expanding population. Governments in the area have been raising their healthcare spending to keep up with the rising demand because they understand how important it is to invest in healthcare, notably pediatric healthcare. The growing awareness and knowledge regarding children's heath is one of the major factors driving the MEA pediatric healthcare industry. Early childhood healthcare is important, and more and more parents and carers are seeking high-quality medical treatment for their kids. Due to the increase in demand for pediatric healthcare services, healthcare providers have been forced to expand their selections. Additionally, the development of the pediatric healthcare market in the MEA region has been significantly influenced by technological improvements. The diagnosis and treatment of pediatric disorders have been enhanced by new diagnostic techniques, cutting-edge medical procedures, and telemedicine options. These technology developments have boosted access to specialised care in far-flung and neglected locations while also improving healthcare results. Pediatric health issues in the MEA region include chronic illnesses, malnutrition, and infectious diseases. The need for pediatric healthcare services has increased as a result of the incidence of these disorders. The region's governments have adopted a number of health-related measures, like as immunisation programmes and nutrition campaigns, which have helped the pediatric healthcare industry expand. The MEA pediatric healthcare market is expanding in large part due to medical tourism. For specialised pediatric treatments, nations like the UAE and South Africa have become major destinations for medical tourism. The expansion of pediatric healthcare facilities and services in these nations has been sparked by this influx of patients. Another important feature of the MEA pediatric healthcare industry is private sector participation. Private healthcare providers have made large investments in the area, enhancing healthcare infrastructure, providing cutting-edge therapies, and enhancing children's access to high-quality care. Thus, driving the Pediatric Healthcare market revenue. ## **Pediatric Healthcare Market Segment Insights** ### **Pediatric Healthcare Type of Diseases Insights** The Middle East and Africa Pediatric Healthcare market segmentation, based on type of diseases includes short term diseases, [chronic diseases](../../../reports/chronic-disease-management-market-981) and others. The short term diseases segment dominated the market, accounting for 41.2% of market revenue. Children are more likely than adults to contract short-term illnesses because of their immature immune systems and intimate social relationships in the community and at school. ### **Pediatric Healthcare Therapeutics Insights** The Middle East and Africa Pediatric Healthcare market segmentation, based on therapeutics, includes cardiology, allergy and immunology, gastroenterology, infectious disease and others. The infectious disease category generated the most income (37.2%). Pathogens like bacteria, viruses, fungi, and parasites are responsible for infectious diseases, which can harm a child's many organ systems. ### **Pediatric Healthcare Treatment Insights** The Middle East and Africa Pediatric Healthcare market segmentation, based on treatment includes medication, surgery and others. The medication segment dominated the market, accounting for 59.2% of market revenue. The administration of pharmacological medications to treat and manage pediatric diseases is a major component of pediatric healthcare. **Figure 1 Middle East and Africa Pediatric Healthcare Market, by Treatment, 2022 & 2032 (USD Billion)** **_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_** ### **Pediatric Healthcare Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The GCC Countries Pediatric Healthcare Market dominated this market in 2022 (45.80%). The development and expansion of pediatric healthcare services in the UAE is facilitated by the availability of specialised facilities, knowledgeable medical personnel, and a dedication to healthcare innovation. **Figure 2 MIDDLE EAST AND AFRICA PEDIATRIC HEALTHCARE MARKET SHARE BY REGION 2022 (USD Billion)** **_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_** South Africa Pediatric Healthcare market accounts for the second-largest market share. This is due to the numerous top-notch hospitals and medical hubs in the area are outfitted with cutting-edge equipment and facilities to deliver complete pediatric healthcare services. The Rest of MEA Pediatric Healthcare Market is expected to grow at the fastest CAGR from 2024 to 2032. Pediatric healthcare services are anticipated to advance due to initiatives to increase accessibility to healthcare, improve the healthcare staff, and use technology. ## **Pediatric Healthcare Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Pediatric Healthcare market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their Middle East and Africa footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Pediatric Healthcare industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Middle East and Africa Pediatric Healthcare industry to benefit clients and increase the market sector. In recent years, the Pediatric Healthcare industry has offered some of the most significant advantages to medicine. Major players in the Pediatric Healthcare market, including Novartis AG (Switzerland), AstraZeneca (UK), Janssen  Services, LLC (Belgium), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), AMMT (Dubai), King Faisal Specialist Hospital and Research Centre (Saudi Arabia), VPS Healthcare (UAE), and others, are attempting to increase market demand by investing in research and development operations. Novartis AG, headquartered in Switzerland, is a major player in the Middle East and Africa (MEA) pediatric healthcare sector and a major worldwide pharmaceutical firm. Novartis focuses on creating cutting-edge medical treatments for a range of pediatric health issues. Novartis is dedicated to enhancing pediatric healthcare in the MEA region by providing a selection of medication made especially for kids. The business makes research and development investments to create secure and efficient solutions for pediatric illnesses. In order to improve access to pediatric healthcare and promote illness prevention and management, Novartis also works with healthcare providers, governments, and nonprofit organizations. AstraZeneca, a leading pharmaceutical company headquartered in the UK. The company focuses on creating and offering cutting-edge drugs and therapies for a range of pediatric health issues. Across order to improve pediatric healthcare access and results, AstraZeneca collaborates with healthcare providers, governments, and non-profit organisations across the MEA area. The business makes investments in research and development to address the distinct healthcare requirements of children in the area, creating drugs and therapies that are suitable for pediatric patients and are both secure and efficient. The dedication of AstraZeneca to pediatric healthcare goes beyond drug development. In order to enhance pediatric health outcomes in the MEA region, the company actively supports collaborations, educational programmers, and campaigns that raise awareness of diseases. AstraZeneca aims to improve disease prevention, early diagnosis, and suitable treatment options for kids across the Middle East and Africa by collaborating closely with healthcare stakeholders. ### **Key Companies in the Pediatric Healthcare market include** - [Novartis AG](https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-pediatric-patients-gastroenteropancreatic-neuroendocrine-tumors) (Switzerland) - AstraZeneca (UK) - Janssen Services - LLC (Belgium) - Eli Lilly and Company (US) - [Bristol-Myers Squibb Company](https://www.bms.com/about-us/responsibility/supporting-our-communities/our-success-stories/the-bristol-meyers-squibb-children-s-hospital-at-robert-wood-joh.html) (US) - AMMT (Dubai) - King Faisal Specialist Hospital and Research Centre (Saudi Arabia) - VPS Healthcare (UAE) ### **Pediatric Healthcare Industry Developments** **May 2018 **Gilenya (fingolimod), manufactured by Novartis AG, is the first disease-modifying drug approved for the treatment of children and adolescents with relapsing forms of multiple sclerosis (RMS), according to the US Food and Drug Administration (FDA). ## **Pediatric Healthcare Market Segmentation** ### **Pediatric Healthcare Type of Diseases Outlook** - Short Term Diseases - Chronic Diseases - Others ### **Pediatric Healthcare Therapeutics Outlook** - Cardiology - Allergy And Immunology - Gastroenterology - [Infectious Disease](../../../reports/apac-infectious-disease-diagnosis-treatment-market-1322) - Others ### **Pediatric Healthcare Treatment Outlook** - Medication - Surgery - Others ## Market Drivers ### Focus on Preventive Healthcare The emphasis on preventive healthcare is becoming increasingly prominent in the Middle East and Africa Pediatric Healthcare Market. Healthcare providers are recognizing the importance of preventive measures in reducing the incidence of childhood diseases. Initiatives such as vaccination programs, nutritional education, and regular health screenings are being prioritized to promote overall child health. This shift towards preventive care is likely to result in a decrease in hospital admissions and long-term healthcare costs. As parents become more aware of the benefits of preventive healthcare, the demand for such services is expected to rise. Consequently, healthcare providers may invest more in preventive programs, thereby enhancing the overall pediatric healthcare landscape in the region. ### Increasing Pediatric Population The Middle East and Africa Pediatric Healthcare Market is experiencing growth due to the rising pediatric population. According to demographic data, the region has one of the highest birth rates globally, contributing to a substantial increase in the number of children requiring healthcare services. This demographic trend necessitates the expansion of pediatric healthcare facilities and services to cater to the growing needs of this population. As the number of children under the age of 14 is projected to reach over 200 million by 2030, healthcare providers are likely to invest in specialized pediatric care, thereby driving the market forward. The increasing demand for pediatric healthcare services is expected to stimulate innovations in treatment and care delivery, enhancing overall healthcare outcomes for children. ### Government Initiatives and Funding Government initiatives aimed at improving healthcare infrastructure are pivotal in the Middle East and Africa Pediatric Healthcare Market. Various governments in the region are allocating significant budgets to enhance healthcare services, particularly for children. For instance, initiatives to build new hospitals and clinics, along with funding for pediatric research, are becoming more prevalent. The World Health Organization has noted that investments in child health can yield substantial returns, potentially reducing long-term healthcare costs. As a result, the focus on pediatric healthcare is likely to increase, with governments prioritizing child health in their national health agendas. This trend may lead to improved access to healthcare services for children, ultimately benefiting the pediatric population. ### Rising Awareness of Child Health Issues There is a growing awareness of child health issues among parents and caregivers in the Middle East and Africa Pediatric Healthcare Market. Educational campaigns and community outreach programs are increasingly emphasizing the importance of regular health check-ups, vaccinations, and preventive care. This heightened awareness is likely to lead to increased demand for pediatric healthcare services, as parents become more proactive in seeking medical attention for their children. Furthermore, the prevalence of non-communicable diseases among children is prompting healthcare providers to focus on early diagnosis and management. As a result, the market may witness a surge in the development of specialized pediatric services and programs aimed at addressing these health concerns. ### Technological Advancements in Healthcare Technological advancements are playing a crucial role in shaping the Middle East and Africa Pediatric Healthcare Market. The integration of telemedicine, electronic health records, and mobile health applications is transforming how pediatric care is delivered. These technologies facilitate better communication between healthcare providers and families, ensuring timely interventions and follow-ups. Moreover, the adoption of advanced diagnostic tools and treatment modalities is enhancing the quality of care for children. As healthcare providers increasingly leverage technology to improve service delivery, the market is likely to expand, driven by the demand for innovative solutions that cater specifically to pediatric needs. This trend may also lead to improved health outcomes for children across the region. ## Future Outlook The Middle East and Africa Pediatric Healthcare Market is projected to grow at 3.84% CAGR from 2025 to 2035, driven by increasing healthcare access, technological advancements, and rising pediatric health awareness. **New opportunities:** - Telehealth platforms for remote pediatric consultations - Development of specialized pediatric pharmaceuticals - Integration of AI-driven diagnostic tools in pediatric care By 2035, the market is expected to be robust, reflecting enhanced healthcare delivery and innovation. ## Segment Insights ### By Type of Diseases: Chronic Diseases (Largest) vs. Short Term Diseases (Fastest-Growing) In the Middle East and Africa Pediatric Healthcare Market, the distribution of diseases in pediatric care reveals a landscape where chronic diseases capture the largest market share, reflecting the growing prevalence of long-term health issues among children. Conditions such as asthma, diabetes, and congenital disorders are increasingly recognized, necessitating long-term care management and treatment options. Meanwhile, short-term diseases, which include common infections and seasonal ailments, are rapidly gaining significance, attributed to increased awareness and improved diagnostic measures within the region. The growth trends within this segment are driven by various factors including urbanization, changing lifestyles, and improved healthcare access in many Middle Eastern and African countries. Parents are increasingly aware of the need for proactive healthcare for their children, leading to a surge in demand for vaccines and preventive measures against both chronic and short-term diseases. Furthermore, public health initiatives aimed at educating families about disease prevention contribute to the rapidly evolving landscape of pediatric healthcare, focusing on both proactive and reactive healthcare strategies. Chronic Diseases (Dominant) vs. Short Term Diseases (Emerging) Chronic diseases represent a dominant category in the pediatric healthcare sector, characterized by their long-lasting impact and continuous management requirements. Common among this classification are conditions like asthma, type 1 diabetes, and congenital abnormalities. These conditions not only require innovative treatment options but also a structured approach towards ongoing healthcare, fostering a robust market for therapeutic agents and management protocols. On the other hand, short-term diseases are emerging rapidly, primarily due to the prevalence of infectious diseases and the impact of environmental factors. The increasing focus on vaccinations and urgent care for acute conditions marks a significant shift toward addressing immediate health concerns, indicating the need for pediatric healthcare providers to adapt to the changing dynamics of disease prevalence in the region. ### By Therapeutics: Cardiology (Largest) vs. Infectious Disease (Fastest-Growing) In the Middle East and Africa Pediatric Healthcare Market, the therapeutics segment is a critical area of focus, with diverse sub-segments like Cardiology, Allergy and Immunology, Gastroenterology, and Infectious Disease contributing to the overall market distribution. Currently, Cardiology stands out as the largest segment, frequently driven by the prevalence of congenital heart defects in the pediatric population, thereby commanding significant attention from healthcare providers and policymakers. On the other hand, Infectious Disease is observing rapid growth, propelled by increased awareness and rising incidences of communicable diseases in children, necessitating effective therapeutic interventions. Cardiology (Dominant) vs. Infectious Disease (Emerging) Cardiology serves as the dominant therapeutic area within the pediatric healthcare landscape of the Middle East and Africa. Reflecting high levels of investment and research, this segment is crucial due to the increasing diagnosis of cardiac conditions among children. The emergence of new therapies and technological advancements in cardiac care is enabling better health outcomes. Conversely, the Infectious Disease segment is considered an emerging area, rapidly gaining traction as public health initiatives address the high burden of infections in pediatric populations. Innovations in treatment protocols and vaccination campaigns are bolstering this segment's growth, indicating a shift towards more collaborative and integrative healthcare approaches. This responsiveness to emerging health challenges underscores the dynamic nature of pediatric healthcare in the region. ### By Treatment: Medication (Largest) vs. Surgery (Fastest-Growing) In the Middle East and Africa Pediatric Healthcare Market, the treatment segment is strategically divided into three primary values: Medication, Surgery, and Others. Among these, Medication holds the largest share, indicating a strong reliance on pharmaceuticals for managing pediatric conditions. Surgery, however, is emerging as the fastest-growing segment, reflecting a shift towards more complex interventions as healthcare infrastructure in the region improves. Others comprise alternative treatment modalities that cater to specialized needs, but they currently hold a smaller market share compared to the other two. Medication: Dominant vs. Surgery: Emerging Medication remains the dominant treatment option in the Middle East and Africa Pediatric Healthcare Market, characterized by a wide range of formulations tailored for pediatric patients. This includes liquid formulations, chewables, and age-appropriate dosing, ensuring ease of administration and adherence to treatment regimens. On the other hand, Surgery is the emerging force, driven by advancements in minimally invasive techniques and increased access to surgical care. This growth is propelled by rising investments in pediatric surgery programs and the establishment of specialized pediatric surgical centers, addressing complex health issues that require surgical intervention. ## Regional Market Share Analysis ### North America : Healthcare Innovation Leader The North American pediatric healthcare market is driven by advanced healthcare infrastructure, high R&D investments, and increasing awareness of child health issues. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 15%. Regulatory support from agencies like the FDA enhances market growth, ensuring safety and efficacy in pediatric treatments. Leading countries in this region include the United States and Canada, with a competitive landscape featuring major players like Pfizer, Johnson & Johnson, and Merck. These companies are focusing on innovative therapies and vaccines tailored for children, addressing specific health challenges. The presence of robust healthcare systems and a strong emphasis on pediatric research further solidify North America's position in the global market. ### Europe : Diverse Healthcare Landscape The European pediatric healthcare market is characterized by diverse healthcare systems and increasing investments in child health initiatives. Germany and France are the largest markets, holding approximately 25% and 20% of the market share, respectively. Regulatory frameworks, such as the EU Pediatric Regulation, promote research and development in pediatric medicines, driving market growth. Key players in this region include Roche, Novartis, and Sanofi, which are actively involved in developing innovative treatments for pediatric patients. The competitive landscape is marked by collaborations between pharmaceutical companies and healthcare providers to enhance pediatric care. Additionally, initiatives aimed at improving access to healthcare services for children are gaining momentum across various European nations. ### Asia-Pacific : Emerging Pediatric Market The Asia-Pacific pediatric healthcare market is witnessing rapid growth due to increasing population, rising healthcare expenditure, and improving access to medical services. China and India are the largest markets, accounting for approximately 30% and 20% of the market share, respectively. Government initiatives aimed at enhancing child health and reducing mortality rates are significant growth drivers in this region. Countries like Japan and Australia are also contributing to market expansion, with a focus on advanced healthcare technologies and pediatric research. The competitive landscape features key players such as GlaxoSmithKline and AstraZeneca, which are investing in innovative solutions tailored for children. The region's growing emphasis on preventive care and early diagnosis is further shaping the pediatric healthcare market. ### Middle East and Africa : Growing Healthcare Initiatives The Middle East and Africa pediatric healthcare market is evolving, driven by increasing investments in healthcare infrastructure and government initiatives aimed at improving child health. The largest markets are South Africa and the UAE, holding approximately 25% and 20% of the market share, respectively. Regulatory bodies are focusing on enhancing healthcare access and quality for children, which is crucial for market growth. Countries like Saudi Arabia and Egypt are also making strides in pediatric healthcare, with a growing presence of key players such as Merck and Johnson & Johnson. The competitive landscape is characterized by partnerships between governments and private sectors to enhance healthcare delivery. Additionally, awareness campaigns focused on child health are gaining traction, further supporting market development. ## Competitive Benchmarking Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Pediatric Healthcare Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their Middle East and Africa footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Pediatric Healthcare industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Middle East and Africa Pediatric Healthcare industry to benefit clients and increase the market sector. In recent years, the Pediatric Healthcare industry has offered some of the most significant advantages to medicine. Major players in the Pediatric Healthcare Market, including Novartis AG (Switzerland), AstraZeneca (UK), Janssen  Services, LLC (Belgium), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), AMMT (Dubai), King Faisal Specialist Hospital and Research Centre (Saudi Arabia), VPS Healthcare (UAE), and others, are attempting to increase market demand by investing in research and development operations. Novartis AG, headquartered in Switzerland, is a major player in the Middle East and Africa (MEA) pediatric healthcare sector and a major worldwide pharmaceutical firm. Novartis focuses on creating cutting-edge medical treatments for a range of pediatric health issues. Novartis is dedicated to enhancing pediatric healthcare in the MEA region by providing a selection of medication made especially for kids. The business makes research and development investments to create secure and efficient solutions for pediatric illnesses. In order to improve access to pediatric healthcare and promote illness prevention and management, Novartis also works with healthcare providers, governments, and nonprofit organizations. AstraZeneca, a leading pharmaceutical company headquartered in the UK. The company focuses on creating and offering cutting-edge drugs and therapies for a range of pediatric health issues. Across order to improve pediatric healthcare access and results, AstraZeneca collaborates with healthcare providers, governments, and non-profit organisations across the MEA area. The business makes investments in research and development to address the distinct healthcare requirements of children in the area, creating drugs and therapies that are suitable for pediatric patients and are both secure and efficient. The dedication of AstraZeneca to pediatric healthcare goes beyond drug development. In order to enhance pediatric health outcomes in the MEA region, the company actively supports collaborations, educational programmers, and campaigns that raise awareness of diseases. AstraZeneca aims to improve disease prevention, early diagnosis, and suitable treatment options for kids across the Middle East and Africa by collaborating closely with healthcare stakeholders. ## Recent News & Developments **May 2018 **Gilenya (fingolimod), manufactured by Novartis AG, is the first disease-modifying drug approved for the treatment of children and adolescents with relapsing forms of multiple sclerosis (RMS), according to the US Food and Drug Administration (FDA). ## Report Scope | MARKET SIZE 2024 | 50.01(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 51.93(USD Billion) | | MARKET SIZE 2035 | 75.71(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.84% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Pfizer (US), Novartis (CH), Sanofi (FR), GlaxoSmithKline (GB), Merck (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Johnson & Johnson (US) | | Segments Covered | Type Of Diseases, Therapeutics, Treatment, Region | | Key Market Opportunities | Integration of telemedicine and digital health solutions enhances access to pediatric healthcare in the region. | | Key Market Dynamics | Rising demand for pediatric healthcare services drives innovation and competition among providers in the Middle East and Africa. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Middle East and Africa Pediatric Healthcare Market?** A: The market valuation was 50.01 USD Billion in 2024. **Q: What is the projected market size for the Middle East and Africa Pediatric Healthcare Market by 2035?** A: The market is projected to reach 75.71 USD Billion by 2035. **Q: What is the expected CAGR for the Middle East and Africa Pediatric Healthcare Market during the forecast period 2025 - 2035?** A: The expected CAGR is 3.84% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the Middle East and Africa Pediatric Healthcare Market?** A: Key players include Roche, Pfizer, Novartis, Sanofi, GlaxoSmithKline, Merck, AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson. **Q: What are the primary segments of the Middle East and Africa Pediatric Healthcare Market?** A: The primary segments include Type of Diseases, Therapeutics, and Treatment. **Q: How much revenue is generated from short-term diseases in the pediatric healthcare market?** A: Revenue from short-term diseases was between 15.0 and 22.0 USD Billion. **Q: What is the revenue range for chronic diseases in the pediatric healthcare market?** A: The revenue range for chronic diseases is between 20.0 and 30.0 USD Billion. **Q: Which therapeutic area generates the highest revenue in the pediatric healthcare market?** A: The 'Others' category in therapeutics generates the highest revenue, ranging from 31.51 to 48.21 USD Billion. **Q: What is the revenue range for surgical treatments in the pediatric healthcare market?** A: Revenue from surgical treatments is projected to be between 15.0 and 25.0 USD Billion. **Q: How does the pediatric healthcare market in the Middle East and Africa compare to other regions?** A: While specific comparisons are not provided, the market's growth trajectory suggests a robust development in pediatric healthcare within the region. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pediatric-healthcare-market-2778*